Home About us Editorial board Current issue Ahead of print Archives Submit article Instructions Subscribe Login  Contact Search
REVIEW ARTICLE
Year : 2015  |  Volume : 6  |  Issue : 2  |  Page : 47-51

Acute porphyria: The drug demon etiology


1 Department of Pharmacology, Fiji National University, Suva, Fiji
2 Department of Prosthodontics, Fiji National University, Suva, Fiji

Correspondence Address:
Sridharan Kannan
Associate Professor, Department of Pharmacology, Fiji National University, Suva
Fiji
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2394-6555.162436

Rights and Permissions

Drugs are one of the important factors that precipitate acute attacks in patients with porphyria. Various in vitro and preclinical animal models exist for determining porphyrogenicity of a drug, but these predictions are not very reliable. Ambiguities still remain with many drugs as to whether they are safe in patients with porphyria. An algorithm for determining the porphyrogenic potential using evidence from anectodotal reports, lipophilicity, affinity of a drug to the Cytochrome enzymes (CYP450), ability to induce or irreversibly inhibit either CYP450 2C9 or CYP450 3A4 and the ability to induce hepatic 5-aminolevulinate synthase has been devised. Management of an acute attack of porphyria involves symptomatic treatment and administration of haem arginate. Several international networks have been initiated that serve as good sources of information for the safe use of drugs to be used in porphyria.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1876    
    Printed66    
    Emailed0    
    PDF Downloaded1803    
    Comments [Add]    

Recommend this journal